BREAKING: Pfizer said it is asking U.S. regulators to authorize its experimental pill for COVID-19, setting the stage for a likely launch of the promising therapy in the coming weeks.
The FDA is holding a public meeting later this month where outside experts will scrutinize a competing drug from Merck, before voting on whether to recommend approval. The FDA isn’t required to convene such meetings and it’s not yet known whether Pfizer’s drug will undergo a similar public review.
Several smaller drugmakers are also expected to seek authorization for their own antiviral pills in coming months. For best results, patients need to start taking the pills within three days of symptoms, underscoring the need for speedy testing and diagnosis. That could be a challenge if another COVID-19 surge leads to testing delays and shortages seen last winter.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
U.S. expected to purchase 10 million courses of Pfizer COVID-19 pill - WaPoEarlier this month, Pfizer, which also makes one of the mostly widely used COVID-19 vaccines, said the pill https://reut.rs/3oxaxnz cut the chance of hospitalization or death for adults at risk of severe disease by 89% in its clinical trial. Pfizer expects to submit interim trial results for the pill, branded Paxlovid, to the Food and Drug Administration (FDA) before the Nov. 25 U.S. Thanksgiving holiday.
Leer más »
Covid-19: Booster jabs for over-40s and Northern Ireland considers Covid passportsFive things you need to know about the coronavirus pandemic this Monday evening.
Leer más »
Pfizer agrees to let other companies make its COVID-19 pillLONDON (AP) — Drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population.
Leer más »
Pfizer signs license agreement to allow broader global access to its experimental Covid-19 antiviral pillPfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental Covid-19 pill.
Leer más »
Pfizer agrees to let other companies make its COVID-19 pillDrugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population. In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population. “It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than 4 billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool, said.
Leer más »